Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-09-19 07:00 |
Biophytis fait le point sur ses programmes d’accès précoce pour Sarconeos (BIO1…
|
French | 182.0 KB | ||
| 2023-09-14 07:00 |
Biophytis renforce sa direction avec la nomination de son Chief Business Offic…
|
French | 191.5 KB | ||
| 2023-09-14 07:00 |
Biophytis Strengthens its Management Team with the Appointment of its Chief Bu…
|
English | 185.4 KB | ||
| 2023-09-11 07:00 |
Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in s…
|
English | 184.7 KB | ||
| 2023-09-11 07:00 |
Biophytis obtient l’autorisation de la FDA pour démarrer l’étude SARA-31 de pha…
|
French | 192.4 KB | ||
| 2023-09-04 23:00 |
Biophytis participera à la 25ème Global Investment Conference de H.C. Wainwrigh…
|
French | 140.6 KB | ||
| 2023-09-04 23:00 |
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conferen…
|
English | 118.4 KB | ||
| 2023-08-16 07:00 |
Biophytis annonce les prochaines étapes règlementaires en Europe et aux Etats-U…
|
French | 192.4 KB | ||
| 2023-08-16 07:00 |
Biophytis announces next regulatory steps in Europe and the United States for …
|
English | 179.4 KB | ||
| 2023-08-08 07:00 |
Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopen…
|
English | 187.3 KB | ||
| 2023-08-08 07:00 |
Biophytis obtient un avis positif pour son étude de phase 3 SARA-31 dans la sar…
|
French | 193.2 KB | ||
| 2023-07-20 07:00 |
Biophytis has requested a pre-submission meeting with the FDA for an Emergency…
|
English | 190.3 KB | ||
| 2023-07-20 07:00 |
Biophytis a requis auprès de la FDA une réunion de pré-soumission d’Autorisati…
|
French | 199.9 KB | ||
| 2023-07-19 07:45 |
Biophytis Announces $3.8 Million Registered Direct Offering
|
English | 182.7 KB | ||
| 2023-07-19 07:45 |
Biophytis annonce un Placement Direct Enregistré de 3,8 millions de dollars
|
French | 198.4 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
